InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1728328
Sentiment: neutral
Topics: corporate-filing, regulation-fd, financial-statements
TL;DR
InMed Pharma filed an 8-K on 7/30, check for Reg FD and financial updates.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on July 30, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at Suite 310, 815 W. Hastings Street, Vancouver, B.C., Canada, V6C 1B4. The company's telephone number is (604) 669-7207.
Why It Matters
This 8-K filing provides an update on InMed Pharmaceuticals Inc.'s corporate information and regulatory disclosures, which is important for investors to stay informed about the company's official filings.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- July 30, 2024 (date) — Date of earliest event reported
- Vancouver, B.C., Canada (location) — Principal Executive Offices
- (604) 669-7207 (phone_number) — Company's telephone number
FAQ
What specific event triggered this 8-K filing?
The filing indicates it is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported on July 30, 2024, and includes items for Regulation FD Disclosure and Financial Statements and Exhibits.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at Suite 310, 815 W. Hastings Street, Vancouver, B.C., Canada, V6C 1B4.
What is the company's telephone number?
The company's telephone number, including area code, is (604) 669-7207.
What is the company's state of incorporation?
The company is incorporated in British Columbia.
What is the SIC code for InMed Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-07-30 15:08:09
Filing Documents
- ea0210292-8k_inmed.htm (8-K) — 42KB
- ea021029201ex99-1_inmed.htm (EX-99.1) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001013762-24-002578.txt ( ) — 269KB
- inm-20240730.xsd (EX-101.SCH) — 3KB
- inm-20240730_lab.xml (EX-101.LAB) — 33KB
- inm-20240730_pre.xml (EX-101.PRE) — 22KB
- ea0210292-8k_inmed_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated July 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: July 30, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2